|Exclusion Criteria:||1) The patient has received prior investigational therapy, chemotherapy, surgery, or radiotherapy within 4 weeks of initiating study drug|
2) The patient has undergone prior thoracic or abdominal surgery within 28 days of study entry, excluding prior diagnostic biopsy.
3) The patient has received radiation therapy to the measurable tumor within 6 months. Patients are allowed to have local irradiation for the management of tumor-related symptoms (bones, brain). However, if a patient has active new disease growing in the previously irradiated site, the patient will be eligible to participate in the study.
4) The patient has a significant medical history or unstable medical condition (unstable systemic disease: congestive heart failure (New York Heart Association Functional Classification class II or worse), recent myocardial infarction within 3 months, unstable angina, active infection (i.e. currently treated with antibiotics), uncontrolled hypertension). Patients with controlled diabetes will be allowed. Patient must be able to undergo procedure for tissue acquisition.
5) The patient has uncontrolled seizure disorder, active neurologic disease, or neuropathy >/= grade 2. Patients with meningeal or CNS involvement by tumor are eligible for the study if the above exclusion criteria are not met.
6) The patient is pregnant (confirmed by serum b-HCG if applicable) or is breastfeeding.
7) Any condition that is unstable or could jeopardize the safety of the patient and its compliance in the study, in the investigator's judgment
8) The patient is actively taking herbal remedies or over-the-counter biologics (e.g., shark cartilage, high dose antioxidants).
9) Patients will be allowed to have prior biologic (i.e. VEGF, EGFR, etc.) therapy. However, the patient will be excluded from a given study if he/she has received the same therapy as the clinical trial (i.e. If a patient has been previously treated with bevacizumab, they are allowed to enroll in any of the 4 studies. If a patient has been previously treated with erlotinib, they are excluded from the clinical trials with erlotinib). In addition, if a patient has been previously treated with gefitinib (Iressa), they are excluded from the clinical trials with erlotinib.
10) Patients must not have undergone minor surgery (e.g., central venous catheter placement) within 24 hours of treatment with ZD6474. Patients may not have undergone any major surgery (e.g. laparotomy, thoracotomy, or craniotomy) within four weeks of enrollment.
11) Patients may not have a history of a bleeding diathesis.
12) Significant cardiovascular event (e.g. myocardial infarction, superior vena cava syndrome (SVC), New York Heart Association (NYHA) classification of heart disease >/=2 within 3 months of entry of presence of cardiac disease that in the opinion of the investigator increases the risk of ventricular arrhythmia
13) History of clinically significant arrhythmia (multifocal PVCs, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTC grade 3) or a symptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded.
14) Prior history of QT prolongation as a result from other medication that required discontinuation of that medication.
15) Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age.
16) QTc with Bazett's correction that is unmeasurable, or >/=480 msec on screening ECG. If a patient has QTc >/=480 msec on screening ECG, the screen ECG may be repeated twice (at least 24 hours apart). The average QTc from the three screening ECGs must be <480 msec in order for the patient to be eligible for the study). If the patient meets eligibility requirements in this way, the "baseline" QTc for this patient will be the average of the 3 ECGs (screen 1, screen 2, and pre-1st dose). Patients who are receiving a drug that has a risk of QTc prolongation are excluded if QTc is >/= 460 msec.
17) Any concomitant medications that affect QTc, induce Torsades de Pointes. (See Appendix A which includes list of relevant medications that have a risk of Torsades de Pointes or QTc prolongation.) Drugs listed in Appendix A, Table 2, that in the investigator's opinion cannot be discontinued, are allowed however, must be monitored closely.
18) Potassium, calcium (ionized calcium or adjusted for albumin), or magnesium concentrations outside normal limits. Supplementation of electrolytes is permitted. Potassium level must be greater than or equal to 4.0 meq/L.
19) Concomitant medications that are potent inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital and St. John's Wort) of CYP3A4 function.
20) Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg)
21) Presence of left bundle branch block (LBBB.)
22) Any unresolved toxicity greater than CTC grade 1 from previous anti-cancer therapy.
23) Currently active diarrhea that may affect the ability of the patient to absorb the ZD6474 or tolerate diarrhea.